肾移植受者免疫检查点抑制剂相关不良事件的基因表达谱分析
本研究采用NanoString技术检测75例肾脏活检组织中725个免疫相关基因的表达,包括25例发现队列和50例验证队列。结果显示免疫检查点抑制剂相关急性间质性肾炎与T细胞介导排斥反应存在显著分子重叠,但IFI27基因表达可有效区分二者(验证队列P<0.001,AUC=100%,准确率86%)。
要点
- 免疫检查点抑制剂相关排斥与急性间质性肾炎分子重叠显著。
- IFI27可区分免疫检查点抑制剂相关T细胞介导排斥与间质性肾炎。
- 两类病变均与药物性间质性肾炎分子更近,提示超敏机制。
核心结论
- 免疫检查点抑制剂相关排斥与急性间质性肾炎分子高度相似,但IFI27表达可作为鉴别生物标志物。
研究设计与样本
- 采用NanoString检测75例存档肾脏活检组织中725个免疫相关基因的表达。
- 发现队列25例含纯T细胞介导排斥和免疫检查点抑制剂相关急性间质性肾炎。
- 验证队列50例含免疫检查点抑制剂相关急性间质性肾炎、T细胞介导排斥、新月体性肾小球肾炎、药物性急性间质性肾炎、BK病毒肾病和正常活检。
主要发现
- 免疫检查点抑制剂相关急性间质性肾炎与T细胞介导排斥存在显著分子重叠。
- IFI27被鉴定并验证为区分免疫检查点抑制剂相关T细胞介导排斥与急性间质性肾炎的新生物标志物。
- 验证队列中IFI27区分二者的P<0.001,AUC=100%,准确率86%。
- 主成分分析显示组内炎症基因表达异质性,但免疫检查点抑制剂相关T细胞介导排斥和急性间质性肾炎均与药物性急性间质性肾炎分子重叠多于T细胞介导排斥。
关键数值与推荐
- IFI27区分免疫检查点抑制剂相关T细胞介导排斥与急性间质性肾炎:验证队列P<0.001,AUC=100%,准确率86%。
临床怎么用
- 活检组织IFI27基因表达检测可能有助于鉴别免疫检查点抑制剂相关排斥与急性间质性肾炎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Immune checkpoint inhibitors are increasingly used to treat various malignancies, but their application in patients with kidney transplants is complicated by high allograft rejection rates. Immune checkpoint inhibitor-associated rejection is a novel, poorly understood entity demonstrating overlapping histopathologic features with immune checkpoint inhibitor-associated acute interstitial nephritis, which poses a challenge for diagnosis and clinical management. We sought to improve the understanding of these entities through biopsy-based gene expression analysis. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: NanoString was used to measure and compare the expression of 725 immune-related genes in 75 archival kidney biopsies, including a 25-sample discovery cohort comprising pure T cell-mediated rejection and immune checkpoint inhibitor-associated acute interstitial nephritis and an independent 50-sample validation cohort comprising immune checkpoint inhibitor-associated acute interstitial nephritis, immune checkpoint inhibitor-associated T cell-mediated rejection, immune checkpoint inhibitor-associated crescentic GN, drug-induced acute interstitial nephritis, BK virus nephropathy, and normal biopsies. RESULTS: Significant molecular overlap was observed between immune checkpoint inhibitor-associated acute interstitial nephritis and T cell-mediated rejection. Nevertheless, IFI27, an IFN-α-induced transcript, was identified and validated as a novel biomarker for differentiating immune checkpoint inhibitor-associated T cell-mediated rejection from immune checkpoint inhibitor-associated acute interstitial nephritis (validation cohort: P<0.001, area under the receiver operating characteristic curve =100%, accuracy =86%). Principal component analysis revealed heterogeneity in inflammatory gene expression patterns within sample groups; however, immune checkpoint inhibitor-associated T cell-mediated rejection and immune checkpoint inhibitor-associated acute interstitial nephritis both demonstrated relatively more molecular overlap with drug-induced acute interstitial nephritis than T cell-mediated rejection, suggesting potential dominance of hypersensitivity mechanisms in these entities. CONCLUSIONS: These results indicate that, although there is significant molecular similarity between immune checkpoint inhibitor-associated rejection and acute interstitial nephritis, biopsy-based measurement of IFI27 gene expression represents a potential biomarker for differentiating these entities.
引用
- Adam BA, Murakami N, Reid G, et al. Gene Expression Profiling in Kidney Transplants with Immune Checkpoint Inhibitor-Associated Adverse Events. Clin J Am Soc Nephrol. 2021. PMID: 34244334. doi:10.2215/CJN.00920121
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。